Cathie Wood’s Ark Invest acquired 13,532 shares of Tempus AI across its ARK Genomic Revolution and ARK Innovation ETFs, representing roughly $925,000 in new positions. This follows Tempus AI’s preliminary report showing an 83% year-over-year revenue increase in 2025, powered by a 111% jump in diagnostics sales. Ark’s added exposure comes a day after it invested an additional $5.85 million in Tempus AI, signaling continued confidence in the company’s growth trajectory and reinforcing its commitment to AI-driven precision medicine.

Tempus AI closed 2025 with a total contract value of $1.1 billion, secured over 70 pharmaceutical data agreements and achieved its first positive adjusted EBITDA in Q3. The company attributed this performance to accelerating adoption of its multimodal data platform among leading biopharma partners and expanded commercial deployment of its genomic and clinical data analytics. These operational milestones underscore Tempus’s ability to convert its large-scale data library into recurring revenue and position it as a strategic partner for drug developers seeking AI-powered insights.

In January 2026, Tempus AI launched Paige Predict, a digital pathology suite that uses AI to analyze H&E whole-slide images and predict the presence of 123 biomarkers across 16 cancer types. Built on a foundation model trained with de-identified data from over 200,000 patients, Paige Predict addresses tissue scarcity by guiding clinicians on optimal sequencing of confirmatory tests. The solution integrates seamlessly with existing workflows, delivering results directly to ordering physicians and reducing delays in obtaining actionable molecular profiles.